Patent intelligence · US
US 12318457
Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof
Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses …
Patent details — US 12318457
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 3, 2025
- Expiration
- May 29, 2045
- Claims
- 10
- CPC classes
- A61K, A61K31/542, A61K31/7016, A61K47/549
Quick answer
US 12318457 (Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof) is held by GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.. Status: granted. Granted Jun 3, 2025. Expires May 29, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/542, A61K31/7016, A61K47/549, A61K47/65, A61K47/68031
More from GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12391720
Salts and polymorphs of cethromycin for the treatment of disease
granted -
US 12377151
Immobilized endoglycosidase fusion protein and use thereof
granted -
US 12370266
Polymer composite nanomaterial encapsulation system
granted -
US 12312377
Biconjugatable labels and methods of use
granted -
US 12195454
Compounds for imaging tau proteins that accumulate in the brain
granted -
US 12102694
Radiolabeled compound producing method and producing apparatus, radiolabeled compound and radioisotope producing apparatus
granted -
US 11999748
Exatecan derivatives, linker-payloads, and conjugates and thereof
granted
Frequently asked questions
What is US patent 12318457?
US 12318457 (Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof) is held by GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.. Status: granted. Granted Jun 3, 2025. Expires May 29, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12318457?
GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 12318457 expire?
Our index shows an expiration date of May 29, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.